Recurrence of autoimmune disease after autologous peripheral blood stem cell transplantation for multiple myeloma

Ikuko Isshiki, Shinichiro Okamoto, Tsunenori Kakimoto, Chien Kang Chen, Takehiko Mori, Kenji Yokoyama, Yutaka Hattori, Yasuo Ikeda

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

There have been a number of reports on the improvement of concomitant autoimmune disease (AID) after autologous hematopoietic stem cell transplantation (SCT) performed for hematologic malignancy. However, in some cases of hematologic malignancy with AID, exacerbation of AID after autologous SCT has been reported. We have treated 27 adults with multiple myeloma with single or tandem autologous SCT. After peripheral blood stem cells were collected and stored without CD34+ cell selection or T-cell depletion, all patients received melphalan (200 mg/m2) as a conditioning regimen. In 2 patients with a history of AID (one with rheumatoid arthritis [RA] and the other with bullous pemphigoid [BP]) and in 1 patient with Sjögren syndrome, AID recurred 7 to 12 months after autologous SCT. The RA and BP were in durable remission before SCT, and no Sjögren syndrome-related disease activity was clinically documented at the time of SCT. No progression of the myeloma was observed when the AIDs recurred. The patients required systemic steroid therapy for their AID, and successful control of the disease was achieved. Our experience suggests that autologous SCT with unmanipulated stem cells for myeloma is unlikely to cure preexisting AID; rather, the AID may worsen. Transplantation physicians should be aware of this possible complication.

Original languageEnglish
Pages (from-to)354-358
Number of pages5
JournalInternational Journal of Hematology
Volume84
Issue number4
DOIs
Publication statusPublished - 2006 Nov

Fingerprint

Peripheral Blood Stem Cell Transplantation
Multiple Myeloma
Autoimmune Diseases
Stem Cell Transplantation
Recurrence
Bullous Pemphigoid
Hematologic Neoplasms
Rheumatoid Arthritis
Preexisting Condition Coverage
Melphalan
Hematopoietic Stem Cell Transplantation
Disease Progression
Stem Cells
Transplantation
Steroids
Physicians
T-Lymphocytes

Keywords

  • Autoimmune disease
  • Autologous stem cell transplantation
  • Immune reconstitution
  • Multiple myeloma
  • Relapse

ASJC Scopus subject areas

  • Hematology

Cite this

Recurrence of autoimmune disease after autologous peripheral blood stem cell transplantation for multiple myeloma. / Isshiki, Ikuko; Okamoto, Shinichiro; Kakimoto, Tsunenori; Chen, Chien Kang; Mori, Takehiko; Yokoyama, Kenji; Hattori, Yutaka; Ikeda, Yasuo.

In: International Journal of Hematology, Vol. 84, No. 4, 11.2006, p. 354-358.

Research output: Contribution to journalArticle

@article{e6ea369f76c44608bf888e09e784394c,
title = "Recurrence of autoimmune disease after autologous peripheral blood stem cell transplantation for multiple myeloma",
abstract = "There have been a number of reports on the improvement of concomitant autoimmune disease (AID) after autologous hematopoietic stem cell transplantation (SCT) performed for hematologic malignancy. However, in some cases of hematologic malignancy with AID, exacerbation of AID after autologous SCT has been reported. We have treated 27 adults with multiple myeloma with single or tandem autologous SCT. After peripheral blood stem cells were collected and stored without CD34+ cell selection or T-cell depletion, all patients received melphalan (200 mg/m2) as a conditioning regimen. In 2 patients with a history of AID (one with rheumatoid arthritis [RA] and the other with bullous pemphigoid [BP]) and in 1 patient with Sj{\"o}gren syndrome, AID recurred 7 to 12 months after autologous SCT. The RA and BP were in durable remission before SCT, and no Sj{\"o}gren syndrome-related disease activity was clinically documented at the time of SCT. No progression of the myeloma was observed when the AIDs recurred. The patients required systemic steroid therapy for their AID, and successful control of the disease was achieved. Our experience suggests that autologous SCT with unmanipulated stem cells for myeloma is unlikely to cure preexisting AID; rather, the AID may worsen. Transplantation physicians should be aware of this possible complication.",
keywords = "Autoimmune disease, Autologous stem cell transplantation, Immune reconstitution, Multiple myeloma, Relapse",
author = "Ikuko Isshiki and Shinichiro Okamoto and Tsunenori Kakimoto and Chen, {Chien Kang} and Takehiko Mori and Kenji Yokoyama and Yutaka Hattori and Yasuo Ikeda",
year = "2006",
month = "11",
doi = "10.1532/IJH97.06029",
language = "English",
volume = "84",
pages = "354--358",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "4",

}

TY - JOUR

T1 - Recurrence of autoimmune disease after autologous peripheral blood stem cell transplantation for multiple myeloma

AU - Isshiki, Ikuko

AU - Okamoto, Shinichiro

AU - Kakimoto, Tsunenori

AU - Chen, Chien Kang

AU - Mori, Takehiko

AU - Yokoyama, Kenji

AU - Hattori, Yutaka

AU - Ikeda, Yasuo

PY - 2006/11

Y1 - 2006/11

N2 - There have been a number of reports on the improvement of concomitant autoimmune disease (AID) after autologous hematopoietic stem cell transplantation (SCT) performed for hematologic malignancy. However, in some cases of hematologic malignancy with AID, exacerbation of AID after autologous SCT has been reported. We have treated 27 adults with multiple myeloma with single or tandem autologous SCT. After peripheral blood stem cells were collected and stored without CD34+ cell selection or T-cell depletion, all patients received melphalan (200 mg/m2) as a conditioning regimen. In 2 patients with a history of AID (one with rheumatoid arthritis [RA] and the other with bullous pemphigoid [BP]) and in 1 patient with Sjögren syndrome, AID recurred 7 to 12 months after autologous SCT. The RA and BP were in durable remission before SCT, and no Sjögren syndrome-related disease activity was clinically documented at the time of SCT. No progression of the myeloma was observed when the AIDs recurred. The patients required systemic steroid therapy for their AID, and successful control of the disease was achieved. Our experience suggests that autologous SCT with unmanipulated stem cells for myeloma is unlikely to cure preexisting AID; rather, the AID may worsen. Transplantation physicians should be aware of this possible complication.

AB - There have been a number of reports on the improvement of concomitant autoimmune disease (AID) after autologous hematopoietic stem cell transplantation (SCT) performed for hematologic malignancy. However, in some cases of hematologic malignancy with AID, exacerbation of AID after autologous SCT has been reported. We have treated 27 adults with multiple myeloma with single or tandem autologous SCT. After peripheral blood stem cells were collected and stored without CD34+ cell selection or T-cell depletion, all patients received melphalan (200 mg/m2) as a conditioning regimen. In 2 patients with a history of AID (one with rheumatoid arthritis [RA] and the other with bullous pemphigoid [BP]) and in 1 patient with Sjögren syndrome, AID recurred 7 to 12 months after autologous SCT. The RA and BP were in durable remission before SCT, and no Sjögren syndrome-related disease activity was clinically documented at the time of SCT. No progression of the myeloma was observed when the AIDs recurred. The patients required systemic steroid therapy for their AID, and successful control of the disease was achieved. Our experience suggests that autologous SCT with unmanipulated stem cells for myeloma is unlikely to cure preexisting AID; rather, the AID may worsen. Transplantation physicians should be aware of this possible complication.

KW - Autoimmune disease

KW - Autologous stem cell transplantation

KW - Immune reconstitution

KW - Multiple myeloma

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=34247205214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247205214&partnerID=8YFLogxK

U2 - 10.1532/IJH97.06029

DO - 10.1532/IJH97.06029

M3 - Article

C2 - 17118763

AN - SCOPUS:34247205214

VL - 84

SP - 354

EP - 358

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 4

ER -